You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long-Term Reliable, High-Power Midwave-Infrared Quantum Cascade Lasers

    SBC: INTRABAND, LLC            Topic: A10AT007

    Intraband, LLC has invented and demonstrated quantum-cascade-laser (QCL) structures that both suppress carrier leakage and have efficient carrier extraction, so-called step-taper active-region (STA) QCLs. As a result, record-high internal efficiencies have been obtained, which are 30-40 % higher than conventional QCLs. Consequently, these midwave infrared (MWIR) semiconductor lasers have potential ...

    SBIR Phase II 2016 Department of DefenseArmy
  2. Next Generation Electronic Warfare Human Machine Interface (HMI) for Submarines

    SBC: SEACORP, LLC            Topic: N151036

    During Phase I, HMI concepts were developed to facilitate work load sharing, collaboration, and interoperability of tools and displays. Attention was given to simplicity and efficiency to reduce the number of menus and button clicks, eliminate windows, and simplify controls to be more intuitive.In Phase II the conceptual displays will be developed into a fully functioning prototype and integrated ...

    SBIR Phase II 2016 Department of DefenseNavy
  3. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Accurate protein folding software to predict ligand induced conformational changes in G protein coupled receptors

    SBC: DNASTAR, INC.            Topic: 100

    Abstract In humans and animals G protein coupled receptors GPCRs are embedded on cell surfaces and function as key regulators of physiological events by transmitting signals from extracellular stimulants across the cell membrane into the cell Impaired or abnormal GPCR function can result in disordered physiological processes causing a broad and diverse range of diseases For this reason GPCRs ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Characterization of a low mutation rate E coli in extended fermentation

    SBC: SCARAB GENOMICS, LLC            Topic: 200

    DESCRIPTION provided by applicant Scarab Genomics was founded to improve E coli as an industrial organism by genome engineering These strains have stable genomes since all prophages transposable and IS elements and the error prone repair systems were removed A recA version has always been provided as an option The goal of the Phase I project was to ascertain whether the changes already in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery

    SBC: Bellbrook Labs, LLC            Topic: 300

    DESCRIPTION provided by applicant Epigenetic regulation of gene expression via methylation has been implicated in diverse diseases including cancer diabetes and inflammation and high throughput screening for histone methyltransferase HMT inhibitors is an area of intense drug discovery effort However there are significant shortcomings with existing HMT enzyme assay methods and these are s ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. An Aging Heart Model for Drug Discovery

    SBC: Invivosciences, Inc.            Topic: NIA

    Project Summary Abstract Cardiovascular drugs are primarily prescribed to older peoplertyears of agesince the prevalence of chronic heart failure and fibrillation increases with ageThe incidence of other diseasesincluding cancer and neurological disordersincreases with agetooAny medications hold potential risks to cause adverse eventsThereforethe risks of medications in older people also increase ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Reducing Health Disparities with a Web Based Learning Management System GURULZ

    SBC: MY COVERAGE PLAN INC.            Topic: NIMHD

    DESCRIPTION provided by applicant My Coverage Plan Inc MCP proposes Reducing Health Disparities with a Web Based Learning Management System GURULZ Reducing uncompensated care helps disparity patients and providers Lack of knowledge about health coverage resources helped create $ billion of uncompensated care in in the U S according to the Kaiser Foundation The andquot GURUL ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers

    SBC: Bellbrook Labs, LLC            Topic: 300

    Project Summary Abstract High throughput screening HTS is a powerful method for the discovery of new drug leads for target enzymes In HTS assays the activity of the target enzyme is often evaluated by quantifying a small molecule or cofactor that is produced or consumed by the enzyme While antibodies are a mainstay of small molecule detection as says they do have severe limitations which a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Microfluidic assay to predict patient-specific multiple myeloma clinical response

    SBC: Lynx Biosciences, Inc.            Topic: 102

    DESCRIPTION provided by applicant Multiple myeloma MM is a debilitating and currently incurable hematological malignancy While the median survival has increased to years MM patients ultimately relapse and become resistant to therapy Once they reach this stage it is often a trial and error process until an effective therapy can be found Furthermore the MM bone marrow tumor microenv ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government